TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02118870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment 90 days DAPT
Description: Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment 360 days DAPT
Description: Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
Study: NCT03617315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylauronic Acid
Description: Schirmer Test, BUT test and OSDI test. Previous and After treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylauronic Acid
Description: Schirmer Test, BUT test and OSDI test. Previous and After treatment
Study: NCT00035100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epothilone b
Study: NCT04989296

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples were obtained following the standard procedures.
Description: Taking 4 ml of peripheral blood from patients on an empty stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples were obtained following the standard procedures.
Description: Taking 4 ml of peripheral blood from patients on an empty stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples were obtained following the standard procedures.
Description: Taking 4 ml of peripheral blood from patients on an empty stomach.
Study: NCT01760382

Intervention type: DEVICE
Intervention: Primary PCI
Description: mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation

Intervention type: DEVICE
Intervention: Primary PCI
Description: mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
Study: NCT00040911

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Undergo electroacupuncture therapy to sham points

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03109535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit + Maptrek
Description: Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit only
Description: Users receive a Fitbit Zip to wear daily.
Study: NCT02545049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: 10 mg or 20 mg Finerenone tablet to be given orally, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be taken orally, once daily.
Study: NCT00286156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
Study: NCT04830657

Intervention type: OTHER
Group type: OTHER
Intervention: Distant reiki
Description: In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distant reiki
Description: In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
Study: NCT00781183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: 6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
Study: NCT00792857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP201 Injection
Description: Comparison of different dose strengths of CTAP201 after single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP201 Injection
Description: Comparison of different dose strengths of CTAP201 after single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxercalciferol
Description: Comparison of different dose strengths of doxercalciferol after single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxercalciferol
Description: Comparison of different dose strengths of doxercalciferol after single dose.
Study: NCT00653198

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT03260062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Early Approaches to Raising Language Skills
Description: The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Speech therapy
Description: Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
Study: NCT01320553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1102 I
Description: SPARC1102 I will be administered in both eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1102 II
Description: SPARC1102 II will be administered in both eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1102 III
Description: SPARC1102 III will be administered in both eyes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle will be administered in both eyes
Study: NCT00614445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
Description: up to 4 tablets daily, titrated according to the protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 to 4 tablets daily titrated according to the protocol
Study: NCT02592720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocktail
Description: Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR
Description: Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: QCA guided group
Description: Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
Study: NCT00868088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDT prior to Mohs surgery
Description: Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PDT prior to Mohs surgery
Description: Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit.
Study: NCT03385915

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
Study: NCT04579536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light curable resin modified glass ionomer varnish
Description: Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
Study: NCT02631369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis OCT device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis OCT device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis OCT device
Study: NCT02172560

Intervention type: DRUG
Intervention: Tiotropium
Study: NCT04738656

Intervention type: DIETARY_SUPPLEMENT
Intervention: Diet plan
Description: Mediterranean style is a non-restricted diet plan compared with the open protein diet plan

Intervention type: DIETARY_SUPPLEMENT
Intervention: Diet plan
Description: Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
Study: NCT05489913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation support program
Description: First of all, a preliminary interview was made with the patients in the experimental group, and their information needs were evaluated individually. Which trainings he should receive and his priorities were determined with the patient. After the training requirements were determined, the general introduction of the website was made and they were allowed to register. Experimental group patients received both training on the website and counseling over the phone for 12 weeks after they started working. A total of 3 phone calls were made with the patients in the first week, 4th and 8th weeks. The interviews lasted an average of 20 minutes. In each phone call, patients were informed and reminded. When patients needed, an average of 2-3 more phone calls were made and information was provided on the subjects they needed.
Study: NCT01437319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A
Description: To be used during run-in phase only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A
Description: To be used during run-in phase only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: To be assigned at randomization at phase 2 only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: To be assigned at randomization during phase 2 only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Assigned to Neophytes during Phase I for a 2-week period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Assigned to Neophytes during Phase I for a 2-week period
Study: NCT01025128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 OH vitamin D
Description: oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
Study: NCT01895569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
Study: NCT04011761

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively
Description: Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
Study: NCT00288288

Intervention type: PROCEDURE
Intervention: Epicardial left ventricular lead placement
Description: Epicardial left ventricular lead placement

Intervention type: PROCEDURE
Intervention: Transvenous left ventricular lead implant
Description: Transvenous left ventricular lead implant
Study: NCT04439500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real World Strategy Training
Description: The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
Study: NCT00280098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
Study: NCT03198234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-allo10
Description: The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-allo10
Description: The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-allo10
Description: The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
Study: NCT03637114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.
Study: NCT04439500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Education
Description: The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
Study: NCT04056702

Intervention type: DRUG
Intervention: Elexacaftor-tezacaftor-ivacaftor exposure
Description: Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
Study: NCT03241706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Fructose
Description: IV fructose (1.3 mg/kg/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline given as a comparison to fructose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: IV infusion of somatostatin (60 ng/kg/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: IV infusion of somatostatin (60 ng/kg/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Somatostatin
Description: IV infusion of somatostatin (60 ng/kg/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV infusion of insulin between 20-60 mU/m2/min.
Study: NCT03287726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
Study: NCT03241706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV infusion of insulin between 20-60 mU/m2/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: IV infusion of insulin between 20-60 mU/m2/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: IV glucagon (0.65 ng/kg/min).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: IV glucagon (0.65 ng/kg/min).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Description: IV glucagon (0.65 ng/kg/min).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose solution
Description: IV dextrose to clamp the plasma glucose at the desired level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose solution
Description: IV dextrose to clamp the plasma glucose at the desired level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose solution
Description: IV dextrose to clamp the plasma glucose at the desired level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Fructose
Description: IV-fructose (6.5 mg/kg/min)
Study: NCT01982994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education/Daily Planning
Description: In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)
Study: NCT05093062

Intervention type: OTHER
Group type: OTHER
Intervention: Tian Jiu Therapy